Fundraising FoxOrgenesis
Germantown, US · Nevada corporation · 2 known investors
Find your way into Orgenesis
Sign up to see every warm intro you have to Orgenesis
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Orgenesis team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Orgenesis provides decentralized manufacturing infrastructure for cell and gene therapies, enabling on-site processing of CGTs in regional centers through its POCare™ platform and OMPUL™ mobile processing units. The company aims to reduce costs, shorten development timelines, and improve patient access to personalized cell and gene therapies.
Founders & leadership
NR
Neil ReithingerCFO2014–2023Neil Reithinger is a CFO with 25+ years of experience across life sciences, consumer products, mining, energy services, and digital media, with background in financial operations, capital markets strategy, and M&A due diligence.
VC
Vered CaplanChief Executive OfficerVered Caplan founded and led multiple life sciences companies in diagnostics, pharmaceuticals, biologics, and medical devices before establishing Orgenesis in 2014 to develop decentralized manufacturing infrastructure for cell and gene therapies.
FF
Ferber FerberExecutive
SF
Sarah FerberExecutive
Board
DS
David SidranskyMember Board of Directors2013–2024Co-Founder and Managing Partner at Israel Biotech Fund
EH
Etti HanochiBoard director
YA
Yaron AdlerBoard director
YY
Yachin YachinBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$33.9M disclosed across 7 rounds · 2014–2024
▶$2.3MraisedMar 2024 · 46 investors · BiotechnologyRule 506(b)
▶$2.3MraisedMar 2024 · 46 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mario PhilipsDirector
- David SidranskyDirector
- Ashish NandaDirector
- Guy YachinDirector
- Vered CaplanExecutive Officer, Director
- Victor MillerExecutive Officer
- Yaron AdlerDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- First sale
- Mar 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1MraisedSep 2023 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedSep 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vered CaplanExecutive Officer, Director
- Yaron AdlerDirector
- Guy YachinDirector
- Mario PhilipsDirector
- Elliot MaltzExecutive Officer
- David SidranskyDirector
- Ashish NandaDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Aug 2023
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$14.8MraisedApr 2022 · 2 investors · BiotechnologyRule 506(b)
▶$14.8MraisedApr 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mario PhilipsDirector
- Neil ReithingerExecutive Officer
- Vered CaplanExecutive Officer, Director
- Guy YachinDirector
- David SidranskyDirector
- Yaron AdlerDirector
- Ashish NandaDirector
- Offering amount
- $14.8M
- Amount sold
- $14.8M
- First sale
- Mar 2022
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$9.2MraisedJan 2020 · 5 investors · BiotechnologyRule 506(b)
▶$9.2MraisedJan 2020 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Neil ReithingerExecutive Officer
- Vered CaplanExecutive Officer, Director
- Sarah FerberExecutive Officer
- Darren HeadExecutive Officer
- Dennis BedoretExecutive Officer
- Guy YachinDirector
- David SidranskyExecutive Officer
- Mario PhilipsDirector
- Ashish NandaExecutive Officer, Director
- Yaron AdlerExecutive Officer
- Offering amount
- $9.2M
- Amount sold
- $9.2M
- Sales commissions
- $739.2K
- Placement agents
- Bean Capital Limited
- First sale
- Jan 2020
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.2MraisedFeb 2018 · 16 investors · BiotechnologyRule 506(b)
▶$1.2MraisedFeb 2018 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Neil ReithingerExecutive Officer
- Guy YachinDirector
- Ferber FerberExecutive Officer
- Ashish NandaDirector
- Vered CaplanExecutive Officer, Director
- Yaron AdlerDirector
- David SidranskyDirector
- Hugues BultotDirector
- Amount sold
- $1.2M
- Sales commissions
- $60K
- Placement agents
- Phoenix Financial Inc.
- First sale
- Jan 2018
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$5.3MraisedDec 2015 · 10 investors · BiotechnologyRule 506(b)
▶$5.3MraisedDec 2015 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David SidranskyDirector
- Etti HanochiDirector
- Yaron AdlerDirector
- Yachin YachinDirector
- Neil ReithingerExecutive Officer
- Vered CaplanExecutive Officer, Director
- Ferber FerberExecutive Officer
- Offering amount
- $10M
- Amount sold
- $5.3M
- First sale
- Dec 2015
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$24KraisedJul 2014 · 1 investors · BiotechnologyRule 506(c)
▶$24KraisedJul 2014 · 1 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Vered CaplanExecutive Officer, Director
- Etti HanochiDirector
- Joseph TenneExecutive Officer
- David SidranskyDirector
- Sarah FerberExecutive Officer
- Yaron AdlerDirector
- Guy YachinDirector
- Offering amount
- $24K
- Amount sold
- $24K
- First sale
- Jul 2014
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
eGenesiseGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
OrganogenesisOrganogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.
Genesis Molecular AIGenesis develops GEMS, an AI platform for drug discovery that identifies and optimizes drug candidates. The company partners with pharmaceutical firms like Incyte and Gilead to accelerate the identification and optimization of new drugs.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies working in the same space as Orgenesis.
In the news
Frequently asked questions
- What does Orgenesis do?
- Orgenesis provides decentralized manufacturing infrastructure for cell and gene therapies, enabling on-site processing of CGTs in regional centers through its POCare™ platform and OMPUL™ mobile processing units. The company aims to reduce costs, shorten development timelines, and improve patient access to personalized cell and gene therapies.
- Who are Orgenesis's investors?
- Orgenesis's investors include Boundary Holding, Israel Biotech Fund.
- How much funding has Orgenesis raised?
- Orgenesis has disclosed $33.9M raised across 7 rounds.
- Where is Orgenesis headquartered?
- Orgenesis is headquartered in Germantown, US.